By Michael Dabaie
Gilead Sciences Inc. (GILD) said it will collaborate with insitro to develop nonalcoholic steatohepatitis therapies.
Under the three-year agreement, insitro's platform will be used to create disease models for NASH and discover targets that have an influence on clinical progression and regression of the disease, Gilead said Tuesday.
Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development.
Insitro will receive an upfront payment of $15 million, with additional near-term payments up to $35 million based on operational milestones. Insitro will be eligible to receive up to $200 million for the achievement of milestones for each of the five Gilead targets and up to low double-digit tiered royalties on net sales.
Write to Michael Dabaie at firstname.lastname@example.org